Predictive methylation signature for gemcitabine sensitivity in pancreatic ductal adenocarcinoma: A pathway to personalized treatment.

被引：0
|
作者：
Sherpally, Deepak
Jeepalyam, Sravan
Puram, Harshitha
Manne, Ashish
机构：
[1] Metropolitan Hosp Ctr, New York, NY USA
[2] Stormont Vail Hlth, Topeka, KS USA
[3] Univ Cincinnati, Cincinnati, OH USA
[4] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.768
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：768 / 768
页数：1
相关论文
共 50 条
  • [1] Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment
    Zhao, Xiao
    Wang, Xiuchao
    Sun, Wei
    Cheng, Keman
    Qin, Hao
    Han, Xuexiang
    Lin, Yu
    Wang, Yongwei
    Lang, Jiayan
    Zhao, Ruifang
    Zheng, Xiaowei
    Zhao, Ying
    Shi, Jian
    Hao, Jihui
    Miao, Qing Robert
    Nie, Guangjun
    Ren, He
    BIOMATERIALS, 2018, 158 : 44 - 55
  • [2] FGFR inhibitors enhance gemcitabine sensitivity in pancreatic ductal adenocarcinoma
    Lin, Qingxiang
    Chaudhuri, Tista Roy
    Straubinger, Ninfa L.
    Ma, Wen Wee
    Straubinger, Robert M.
    CANCER RESEARCH, 2017, 77
  • [3] Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
    Shao, Feng
    Huang, Mei
    Meng, Futao
    Huang, Qiang
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [4] A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
    Nicolle, R.
    Gayet, O.
    Duconseil, P.
    Vanbrugghe, C.
    Roques, J.
    Bigonnet, M.
    Blum, Y.
    Elarouci, N.
    Armenoult, L.
    Ayadi, M.
    de Reynies, A.
    Puleo, F.
    Augustin, J.
    Emile, J. F.
    Svrcek, M.
    Arsenijevic, T.
    Hammel, P.
    Giovannini, M.
    Grandval, P.
    Dahan, L.
    Moutardier, V
    Gilabert, M.
    Van Laethem, J. L.
    Bachet, J. B.
    Cros, J.
    Iovanna, J.
    Dusetti, N. J.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 250 - 260
  • [5] Gemcitabine resistance in pancreatic ductal adenocarcinoma
    Binenbaum, Yoav
    Na'ara, Shorook
    Gil, Ziv
    DRUG RESISTANCE UPDATES, 2015, 23 : 55 - 68
  • [6] Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma
    Sebastian, Nikhil T.
    Webb, Amy
    Merrell, Kenneth W.
    Koay, Eugene J.
    Wolfe, Adam R.
    Zhang, Lizhi
    Wilhite, Tyler J.
    Elganainy, Dalia
    Robb, Ryan
    Chen, Wei
    Cloyd, Jordan
    Dillhoff, Mary
    Tsung, Allan
    Abushahin, Laith
    Noonan, Anne
    Williams, Terence M.
    CANCERS, 2021, 13 (20)
  • [7] Targeting tumor microenvironment with gemcitabine is useful for the treatment of pancreatic ductal adenocarcinoma
    Tada, Motohisa
    Ijichi, Hideaki
    Miyabayashi, Koji
    Saoka, Yoshinari A.
    Mohri, Dai
    Ikenoue, Tsuneo
    Mikata, Rintarou
    Tawada, Katsunobu
    Ishihara, Takeshi
    Kanai, Fumihiko
    Imazeki, Fumio
    Omata, Masao
    Moses, Harold L.
    Yokosuka, Osamu
    CANCER RESEARCH, 2012, 72
  • [8] The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
    Lu, Hao
    Zheng, Li-Yan
    Wu, Ling-Yan
    Chen, Jun
    Xu, Na
    Mi, Sui-Cai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA
    Huanwen Wu
    Shiwei Guo
    Xiaoding Liu
    Yatong Li
    Zhixi Su
    Qiye He
    Xiaoqian Liu
    Zhiwen Zhang
    Lianyuan Yu
    Xiaohan Shi
    Suizhi Gao
    Huan Wang
    Yaqi Pan
    Chengcheng Ma
    Rui Liu
    Menghua Dai
    Gang Jin
    Zhiyong Liang
    BMC Medicine, 20
  • [10] Advanced Gene Signatures for the Diagnosis and Personalized Treatment of Pancreatic Ductal Adenocarcinoma
    Puram, Harshitha
    Sherpally, Deepak
    Jeepalyam, Sravan
    Manne, Ashish
    CANCER RESEARCH, 2024, 84 (17)
12345